How much funding has Aviceda Therapeutics raised?

Aviceda Therapeutics has raised $272.6M in total funding, most recently a Series C round.

Who are Aviceda Therapeutics's investors?

Aviceda Therapeutics's investors include Omega Funds, TCG Crossover, Longitude Capital, Enavate Sciences, Catalio Capital Management, Blue Owl Capital.

When was Aviceda Therapeutics founded?

Aviceda Therapeutics was founded in 2018.

Where is Aviceda Therapeutics headquartered?

Aviceda Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Aviceda Therapeutics in?

Aviceda Therapeutics operates in Biotech, Healthcare.

How many employees does Aviceda Therapeutics have?

Aviceda Therapeutics has 51-200 employees.

Aviceda Therapeutics

The Future of Glyco-therapeutics

Cambridge, United States · Founded 2018 · $272.6M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2018
Business Model: B2B

Total Funding: $272.6M
Last Round: $207.5M Series CJan 2025
Rounds: 3

About

Aviceda Therapeutics is a late clinical-stage biotechnology company focused on harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation. Using its proprietary HALOS nanoparticle platform, Aviceda develops glyco-immune checkpoint therapeutics targeting devastating ocular, systemic degenerative, fibrotic, and immuno-inflammatory diseases. The company's lead asset AVD-104 has advanced into Phase 2 clinical trials for geographic atrophy, backed by over $207.5M in Series C financing.

Summary

Aviceda Therapeutics is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $272.6M in total across 3 rounds, most recently a $207.5M Series C round in Jan 2025. Investors include Omega Funds, TCG Crossover and Longitude Capital.